Amgen Seeks Korean Partners in AI Drug Discovery, Obesity

{
  "signal_id": "551daa5e-4a6a-0507-93be-94040944b212",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-09-07T22:01:05+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://en.sedaily.com/finance/2026/09/08/amgen-seeks-korean-partners-in-ai-drug-discovery-obesity",
    "title": "Amgen Seeks Korean Partners in AI Drug Discovery, Obesity - Seoul Economic Daily",
    "excerpt": "\"Amgen is looking for potential partners in Korea for drug discovery using artificial intelligence and data,\" said Helen Kim, vice president of business development at Amgen. \"To work with Amgen, it is important to have strategic alignment, scientific differentiation and the capability to solve problems.\" In an interview with The Seoul Economic Daily on the 7th, Kim said AI and data science can not only improve the efficiency of drug discovery and development and shorten timelines, but also help identify therapeutic opportunities that were previously difficult to find. Kim is responsible for identifying and evaluating early-stage business development opportunities and pursuing deals across all therapeutic areas, from small-molecule compounds to biologics platforms, AI-based drug development platforms and precision medicine. Korea is one of the key countries Amgen is watching as an innovation partner. In 2024, the company brought Amgen Golden Ticket, an open innovation program designed to nurture biotech firms, to Korea. It was the fifth country in the world and the second in Asia to host the program. \"When we were running pitching days with the Korea Health Industry Development Institute starting in 2021 to identify innovative companies, we had already confirmed Korea's outstanding scientific talent and dynamic entrepreneurial spirit, which led us to decide to introduce the...",
    "product": "generative AI models for drug discovery",
    "summary": "Amgen has signed an agreement with Nvidia to build generative AI models for drug discovery.",
    "planning": false,
    "image_url": "https://wimg.sedaily.com/news/cms/2026/09/07/news-p.v1.20260904.9406a6c47a39433d8c57d75011326458_P1.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "generative AI models for drug discovery",
      "full_text": "generative AI models for drug discovery",
      "fuzzy_match": false,
      "release_type": "model"
    },
    "product_tags": [
      "future_tech",
      "general_technology",
      "data"
    ],
    "published_at": "2026-09-07T22:01:05Z",
    "article_sentence": "It has also signed an agreement with Nvidia to build generative AI models for drug discovery.",
    "related_company_name": "Nvidia",
    "related_company_domain": "nvidia.com"
  }
}

curl https://signals.autobound.ai/v1/signals/551daa5e-4a6a-0507-93be-94040944b212 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'